Use of non-vitamin K antagonist oral anticoagulants is spreading in the real world. Despite that, a strong need for antidotes/reversal agents is still reported by several physicians. Idarucizumab is a humanized monoclonal antibody fragment that binds specifically to dabigatran. Idarucizumab was approved in 2015 by the US Food and Drugs Administration and European Medicines Agency for reversal of anticoagulation activity in dabigatrantreated patients. This review briefly summarizes the experimental evidence about effectiveness and safety of idarucizumab. Furthermore, we review the current recommendations and experts' point of view about the use of antidotes/reversal agents in patients reporting a major bleeding event.

Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal / Proietti, Marco; Boriani, Giuseppe. - In: THERAPEUTICS AND CLINICAL RISK MANAGEMENT. - ISSN 1176-6336. - 14:(2018), pp. 1483-1488. [10.2147/TCRM.S140377]

Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal

Proietti, Marco
Primo
;
2018

Abstract

Use of non-vitamin K antagonist oral anticoagulants is spreading in the real world. Despite that, a strong need for antidotes/reversal agents is still reported by several physicians. Idarucizumab is a humanized monoclonal antibody fragment that binds specifically to dabigatran. Idarucizumab was approved in 2015 by the US Food and Drugs Administration and European Medicines Agency for reversal of anticoagulation activity in dabigatrantreated patients. This review briefly summarizes the experimental evidence about effectiveness and safety of idarucizumab. Furthermore, we review the current recommendations and experts' point of view about the use of antidotes/reversal agents in patients reporting a major bleeding event.
2018
anticoagulant drugs; idarucizumab; major bleeding; non-vitamin K antagonist oral anticoagulants; reversal agents
01 Pubblicazione su rivista::01a Articolo in rivista
Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal / Proietti, Marco; Boriani, Giuseppe. - In: THERAPEUTICS AND CLINICAL RISK MANAGEMENT. - ISSN 1176-6336. - 14:(2018), pp. 1483-1488. [10.2147/TCRM.S140377]
File allegati a questo prodotto
File Dimensione Formato  
Proietti_Use of idarucizumab_2018.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 985 kB
Formato Adobe PDF
985 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1189271
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 3
social impact